Background We tested the hypotheses that long-term administration of the angiotensin-converting enzyme (ACE) inhibitor fosinopril will regress hypertrophy, modify the transition to heart failure, and prolong survival in rats with chronic left ventricular (LV) pressure overload due to ascending aortic stenosis.
Background We tested the hypotheses that long-term administration of the angiotensin-converting enzyme (ACE) inhibitor fosinopril will regress hypertrophy, modify the transition to heart failure, and prolong survival in rats with chronic left ventricular (LV) pressure overload due to ascending aortic stenosis.
Methods and Results Aortic stenosis was created in weanling male Wistar rats by a stainless steel clip placed on the ascending aorta. Age-matched control animals underwent a sham operation (Sham group, n=57). Six weeks after surgery, rats with aortic stenosis were randomized to receive either oral fosinopril 50 mg * kg`1 d-1 (Fos/LVH group, n=38) or no drug (LVH group, n=36) for 15 weeks. Pilot studies confirmed that this dosage produced significant inhibition of LV tissue ACE in vivo. Animals were monitored daily, and survival during the 15-week treatment period was assessed by actuarial analysis. At 15 weeks, in vivo LV systolic and diastolic pressures and heart rate were measured. To assess contractile function, the force-calcium relation was evaluated by use of the isovolumic buffer-perfused, balloon-in-LV heart preparation at comparable coronary flow rates per gram LV weight. Quantitative morphometry was performed. Mortality during the 15-week trial was significantly less in the Fos/LVH group than in the LVH group (3% versus 31%, P<.005). No Angiotensin-converting enzyme (ACE) inhibition h hasbeen shown to improve survival in patients LkX with advanced heart failure,' delay the development of heart failure in patients with asymptomatic eral resistance, thereby unloading the LV. 16 However, recent studies from our laboratory and others have suggested that local cardiac tissue ACE and the reninangiotensin system are activated in animal models of heart failure17 and cardiac hypertrophy. [18] [19] [20] Although the efficacy of ACE inhibitors in prolonging survival in heart failure and reversing cardiac hypertrophy has been recognized, it has been difficult to dissociate the systemic hemodynamic effects of ACE inhibition on left systolic pressure from the effects of blockade of cardiac tissue ACE. Furthermore, whereas prior studies have suggested that ACE inhibition prevents or regresses LV hypertrophy in rats with aortic banding, it is unclear whether interference with cardiac hypertrophy in the presence of persistent pressure overload has a beneficial or adverse effect on long-term survival and cardiac function. 14,15,19,2' To address these issues, we used male Wistar rats with pressure-overload LV hypertrophy caused by experimental ascending aortic stenosis. We have shown that this model, which is characterized by the absence of systemic hypertension, is associated with a stage of compensated concentric LV hypertrophy 6 to 8 weeks after banding that is followed by later decompensation, with premature death 20 weeks after banding.22 Fur- thermore, at the early stage of compensated hypertrophy, we have shown that LV cardiac ACE activity and mRNA levels are elevated and associated with an increased local intracardiac generation of angiotensin II that is blocked by specific ACE inhibition.23 '24 We hypothesized that if the activation of the cardiac tissue renin-angiotensin system contributed to the development of hypertrophy and subsequent failure, then chronic administration of the ACE inhibitor fosinopril would decrease the extent of hypertrophy and favorably modify the transition to cardiac failure in rats with established LV hypertrophy despite persistent severe elevation of LV systolic pressure overload due to ascending aortic constriction. Six weeks after aortic banding, rats were randomized to 15 weeks of oral fosinopril therapy or no drug, with age-matched sham-operated controls. We studied the effects of chronic fosinopril treatment on survival, organ and cellular hypertrophic remodeling, and LV systolic and diastolic function assessed in vivo and in the isolated heart preparation.
We demonstrate in this study for the first time that the effects of ACE inhibition on LV hypertrophy can be dissociated from the elevation of LV systolic pressure and that chronic treatment with the ACE inhibitor fosinopril improves survival and improves cardiac function despite severe persistent elevation of LV systolic pressure. Perfusion Technique
Methods

Preparation of Animals
At the end of the 15-week treatment period (21 weeks after aortic banding), eight Fos/LVH, six LVH, and six Sham rats were killed, and the isolated hearts were subjected to hemodynamic evaluation using the isovolumic buffer-perfused rat heart preparation previously described in detail.2324 Body weight was recorded. The rats were anesthetized with intraperitoneal sodium pentobarbital, and the thorax was rapidly opened. Within 20 seconds, the heart was removed and perfused by a constant-flow pump (MasterFlex; Cole-Parmer Instrument Co) through a short cannula inserted into the aortic root just below the level of the aortic clip. The hearts were placed in a constant-temperature chamber and maintained at 36°C. The perfusate consisted of modified Krebs-drainage. A thermistor and a pacing electrode were inserted into the right ventricle via the right atrium and tied in place. A collapsed latex balloon, slightly larger than the LV chamber such that no measurable pressure was generated by the balloon itself over the range of volumes used, was placed in the LV, and LV pressure was measured via a Statham P23Db pressure transducer (Gould Instruments) connected to the balloon via a short length of stiff polyethylene tubing. Coronary perfusion pressure was measured from a side arm of the aortic perfusion cannula connected to a second Statham P23Db pressure transducer. The coronary flow rate was measured by timed collection of the samples of coronary venous effluent.
The hearts were perfused for a stabilization period of 20 minutes at a paced heart rate of 240 beats per minute, which was continued throughout the experiment. In hearts from rats with aortic stenosis, coronary flow rate was adjusted to achieve a mean coronary perfusion pressure of 110 mm Hg and was then held constant throughout the experiment. In shamoperated control animals, coronary flow rate was adjusted to achieve a mean coronary perfusion pressure of 75 mm Hg and was then held constant throughout the experiment. These differing levels of flow and perfusion pressures were chosen in recognition of the difference between the in vivo coronary perfusion pressure to which the control and aortic stenosis groups were chronically exposed and because prior experience with these hearts showed that this approach would achieve comparable myocardial perfusion flow rates per gram of I V weight. [22] [23] [24] At the end of the stabilization period, LV filling curves were generated. The Plasma Norepinephrine Levels, Renin Activity, and ACE Activity Plasma norepinephrine, renin activity, and ACE activity were determined in 8 Fos/LVH, 7 LVH, and 8 Sham animals. Plasma norepinephrine was determined by a radioenzymatic assay using the enzyme carbachol-O-methyl transferase (COMT).29 Four milliliters of blood was collected into chilled tubes containing reduced glutathione and ethylene-bis(oxyethylene-nitrile)-tetraacetic acid and placed on ice. Within 60 minutes of collection, blood was centrifuged at 30 OOOg at 4°C for 20 minutes to separate the plasma. Plasma was stored at -80°C and was assayed within 12 weeks of collection. Plasma was deproteinized with perchloric acid and then incubated with COMT and [3H]methyl-S-adenosyl-L-methionine to convert norepinephrine to [3H]normetanephrine. This was subsequently extracted and separated by thin-layer chromatography and quantified by liquid scintillation counting. The intra-assay coefficient of variation for norepinephrine in this assay was 4%, whereas interassay coefficient of variation was 5.14%.
Plasma renin activity was measured by the method described by Sealy and Laragh.30 Blood was collected into chilled tubes containing EDTA, was kept on ice, and was processed and stored as for plasma norepinephrine assay. To measure plasma renin activity, one aliquot of the sample was incubated at 37°C for 30 minutes and another for 3 hours. After this, the samples were plunged into an ice bath to stop the renin activity. Then, a standard radioimmunoassay was done using 125I-angiotensin I. The results were calculated with the standard curve that runs concurrently with each assay. ACE activity was measured with a radiometric assay (Ventrex Laboratories) that uses radiolabeled [3H]Hip-Gly-Gby, which is converted by ACE to [3H]hippuric acid. 31 Measurements of LV High-Energy Phosphate and Hydroxyproline Levels Myocardial ATP and creatine phosphate contents of six Fos/LVH, seven LVH, and six Sham hearts were analyzed by standard enzymatic methods.32 At the end of a 30-minute control period of oxygenated perfusion, the heart was trimmed of atria and right ventricle, and, while still being perfused, the LV was rapidly frozen with aluminum clamps that had been cooled in liquid nitrogen. Frozen samples of LV myocardium were stored in liquid nitrogen. The frozen myocardial sample was rapidly weighed and pulverized in a mortar under liquid nitrogen. A portion of the frozen powder was weighed and subsequently dried at 37°C for 48 hours to determine the ratio of frozen to dry weight; the remainder of the frozen pulverized specimen was ground with 0.6N perchloric acid and homogenized with a glass tissue homogenizer. The homogenate was centrifuged, and the supernatant was neutralized with 5 mol/L K,C03. Aliquots of the neutralized homogenate were then analyzed for ATP by the methods of Adams32 by use of preweighed reagent vials (catalog number 336 UV, Sigma Chemical Co). The creatine phosphate was measured by adding an excess of creatine kinase to the ATP assay reaction be estimated by the calculation of LV systolic wall stress, which is directly related to the magnitude of LV pressure and cavity radius and indirectly related to wall thickness and mass. In this prospective survival trial, animals were not chronically instrumented or withdrawn for experimentation during the trial, so serial calculations of wall stress are not available. Nonetheless, the in vivo LV pressure data and serial echocardiographic data afford insights into the changes in load in this model. In contrast with dilated cardiomyopathy, the predominant hemodynamic perturbation in chronic valvular aortic stenosis or ascending aortic banding is the elevation of LV systolic pressure in the absence of cavity dilatation or depression of systolic fiber shortening. This stimulates the hypertrophic response of the parallel addition of myofibrils and an increase in wall thickness that tends to restore wall stress to normal.37 In this study, in vivo echocardiographic data obtained 6 weeks after banding before initiation of the treatment trial showed that the rats with ascending aortic stenosis exhibited these hallmarks of LV pressure overload: LV end-systolic and end-diastolic dimensions were not increased and fractional shortening was not impaired relative to age-matched controls, whereas LV mass was increased. Thus, in contrast to patients with dilated cardiomyopathy, it is highly unlikely that the effects of fosinopril therapy appeared to prevent the development of the depression of LV fractional shortening and an increase in systolic cavity dimension, which occurred in the untreated aortic stenosis animals. Heart rate was similar in all groups. Thus, taken together, these data support the hypothesis that the beneficial effects of ACE inhibition on the regression of hypertrophy and survival in the fosinopril-treated rats occurred in the absence of the reduction of LV systolic pressure or serial changes in LV cavity dimensions, contractility, or heart rate.
Regression of LV Hypertrophy
Chronic ACE inhibition significantly reduced the extent of LV hypertrophy and altered the composition of the myocardium. At the cellular level, ACE inhibition resulted in a significant reduction in myocyte width of aortic-banded rats such that myocyte width was similar to that of sham-operated normal hearts. Cell length was similar in LV myocytes from aortic-banded rats treated with ACE inhibition versus no drug, suggesting that ACE-induced changes in myocyte remodeling occurred predominantly via alterations in the parallel addition of myofibrils, which characterizes pressure-overload hypertrophy. 37 Quantitative morphometry showed that the regression of myocyte hypertrophy was not accompanied by proportional changes in other components of the myocardium. Although this model is not associated with the severe fibrosis and elevation of collagen content that is detected in some patients with advanced hypertrophy38 and in some animal models of experimental pressure overload,39 the untreated rats with aortic stenosis exhibited a modest increase in the volume fraction of fibrillar collagen relative to the sham-operated control rats. In the aortic stenosis rats treated with ACE inhibition, the reduction of myocyte width and myocyte volume fraction was associated with a relative increase in total interstitial volume fraction composed largely of a twofold increase in the volume fraction of fibrillar collagen. In this study, we do not know whether a qualitative change in collagen type also occurred.
The relative increase in interstitial fibrillar collagen may be related in part to the notion proposed by Weber et 
Summary
In summary, we demonstrated that chronic treatment with the ACE inhibitor fosinopril markedly improved survival, regressed myocyte hypertrophy, and modified the transition to failure in rats with ascending aortic stenosis despite persistent severe elevation of LV systolic pressure. These data provide support for the concept that the renin-angiotensin system contributes to the transition from compensated hypertrophy to failure and premature death distinct from the stimulus of the elevation of LV systolic pressure.
